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The oxidized form of purple acid phosphatase from pig allantoic ¯uid
has been crystallized in the presence of phosphate using the hanging-
drop technique. The crystals belong to the space group P212121 and
have unit-cell parameters a = 66.8, b = 70.3, c = 78.7 AÊ . Diffraction
data collected from a cryocooled crystal using a conventional X-ray
source extend to 1.55 AÊ resolution. A knowledge of the three-
dimensional structure of mammalian purple acid phosphatase will aid
in understanding the substrate speci®city of the enzyme and will be
important in the rational design of inhibitors, with potential in the
treatment of bone diseases.
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1. Introduction
Mammalian purple acid phosphatase (E.C.
3.1.3.2) is a 35 kDa monomeric glycoprotein
which catalyses the hydrolysis of a broad range
of phosphomonoesters. The enzyme is char-
acterized by a spin-coupled redox-active
binuclear FeIII±FeII/III centre essential for
enzymatic activity. The distinctive purple
colour of the enzyme results from a charge-
transfer transition at 560 nm between a tyro-
sine and the ferric ion. When the enzyme is
reduced to the active FeIII±FeII form, the
charge-transfer band moves to 515 nm,
resulting in the protein having a pink colour.
To date, no experimental structures of
mammalian purple acid phosphatase are
available, although the structure of a purple
acid phosphatase from red kidney bean has
been determined to 2.65 AÊ resolution (StraÈ ter
et al., 1995; Klabunde et al., 1996). Structures of
phosphate-bound and tungstate-bound
complexes have also been determined to 2.7
and 3.0 AÊ resolution, respectively (Klabunde et
al., 1996). Like mammalian purple acid phos-
phatase, red kidney bean purple acid phos-
phatase is a glycoprotein; however, it is a
homodimer rather than a monomer and has a
much larger subunit molecular weight of
55 kDa. Also in contrast to mammalian purple
acid phosphatase, the binuclear centre in the
red kidney bean structure is FeIII±ZnII and is
not redox active. Based on the red kidney bean
crystal structure and a sequence alignment, a
tentative model was proposed for the
mammalian purple acid phosphatases
(Klabunde et al., 1995). In the red kidney bean
structure, residues Asp135, Asp146, Tyr167,
Asn201, His286, His323 and His325 provide
ligands to the metal ions. These residues are
completely conserved in the mammalian
enzymes, which suggests that the active-site
structures in the near vicinity of the metal
centre will be very similar. However, the
mammalian and plant enzymes share less than
20% sequence identity, indicating that there
are likely to be structural differences away
from the metal centre. The known mammalian
purple acid phosphatases (human, rat, mouse,
pig and cow) exhibit sequence identities of
85% or more. Thus, the three-dimensional
structure of any of these proteins should
provide an excellent model for all the others.
We have chosen to study the pig enzyme, also
called uteroferrin to highlight its likely role in
iron transport from mother to foetus (Schlos-
nagle et al., 1974; Baumbach et al., 1986). It is
present in large quantities in pig allantoic ¯uid
and this is an excellent source for puri®cation
(Chen et al., 1973).
Mammalian purple acid phosphatase, of
which pig is the best characterized, is also
commonly referred to as tartrate-resistant acid
phosphatase (TRAP) because, unlike some
other mammalian acid phosphatases, it is not
inhibited by l-(+)-tartrate. It has also been
called type 5 acid phosphatase, based on its
electrophoretic mobility. These names re¯ect
the widespread use of this enzyme as a marker
for osteoclasts. Experiments with transgenic
mice support a role for the enzyme in bone
resorption by osteoclasts (Hayman et al., 1996).
Inhibitors of human purple acid phosphatase
thus have potential as drugs for the treatment
of bone diseases such as osteoporosis. The
crystal structures of the mammalian enzyme
will be critical for the structure-based design of
such inhibitors.
2. Materials and methods
2.1. Puri®cation and preparation
Purple acid phosphatase was obtained from
the allantoic ¯uid of 65-day pregnant sows and
was puri®ed as described previously (Campbell
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et al., 1978). SDS±PAGE analysis showed
that the protein was >95% pure. Dynamic
light-scattering experiments using a
DynaPro 801 indicated that the protein was
monodisperse and, therefore, well suited to
crystallization trials (FerreÂ -D'AmareÂ &
Burley, 1994). Prior to crystallization, the
protein was reduced by addition of 58 mM
ferrous ammonium sulfate and 0.1 M
-mercaptoethanol. Addition of excess
phosphate led to complete and essentially
irreversible oxidation through formation of
the oxidized enzyme±phosphate complex
(Keough et al., 1982). The speci®c activity of
the reduced protein was 8.05 
10ÿ6 mol sÿ1 mgÿ1, while the speci®c activity
after oxidation and in the presence of
phosphate was 3.7  10ÿ7 mol sÿ1 mgÿ1.
2.2. Crystallization
Crystals of the oxidized purple acid
phosphatase±phosphate complex were
obtained by the hanging-drop vapour-diffu-
sion method and a microseeding technique.
Initial conditions were found using the
sparse-matrix screening approach (Jancarik
& Kim, 1991). Clusters of
needle-shaped crystals,
purple in colour, were
produced from a solution
which contained equal
volumes of well solution A
[25%(w/v) PEG 3350,
20%(v/v) 2-propanol and
0.1 M LiCl in 0.1 M sodium
citrate pH 5.0] and a
38 mg mlÿ1 solution of the
oxidized enzyme±phos-
phate complex. For micro-
seeding, the needle-shaped
crystals were crushed into
small fragments and the
mixture of droplet and
crystal fragments was
placed in an Eppendorf
tube. This solution was
then diluted tenfold with
well solution A. Larger
single crystals (Fig. 1) were obtained by
streak seeding into a drop which contained
equal volumes of well solution B [25%(w/v)
PEG 3350, 0.1 M LiCl and 5%(v/v) 2-
propanol in 0.1 M sodium citrate pH 5.0]
and a 38 mg mlÿ1 solution of oxidized
enzyme±phosphate complex. After one
month, the crystals reached a maximum size
of 0.8  0.15  0.1 mm (Fig. 1).
2.3. Cryocooling and data collection
Crystals were cryoprotected by soaking
for 3 min in well solution B incorporating
15%(v/v) glycerol, followed by a further
1 min soak in well solution B incorporating
32%(v/v) glycerol. After this procedure, the
crystals were placed directly into the
nitrogen stream at 100 K (Oxford Cryosys-
tems Cryostream) for data collection. X-ray
diffraction experiments were carried out
using a Rigaku RU-200 Cu K rotating-
anode generator (equipped with Yale
focusing mirrors) operating at 46 kV and
60 mA. The X-ray diffraction data were
recorded on an R-AXIS IIC imaging-plate
area detector and were integrated and
scaled with the programs DENZO and
SCALEPACK (Otwinowski & Minor,
1997).
3. Results and discussion
Attempts to crystallize this enzyme trace
back almost 20 years. The lack of success
may have been because of heterogeneity
and glycosylation. In the present work, a
micro-heterogeneity problem resulting from
the possible coexistence of several enzyme
forms in solution (reduced, oxidized, phos-
phate complexes, apoproteins) has been
eliminated by converting the enzyme to a
single molecular form, the very stable
oxidized enzyme±phosphate complex. The
formation of a single species prior to crys-
tallization could be important for diffraction
quality. For example, a report from 1994 of
small needle-like crystals (0.25  0.05 
<0.05 mm) of human purple acid phospha-
tase (Hayman & Cox, 1994) provided no
details of diffraction data quality and has not
yet yielded a published crystal structure.
Preliminary analysis of our crystals at
room temperature showed that they
belonged to the space group P212121 with
unit-cell parameters a = 66.8, b = 70.3,
c = 78.7 AÊ . Initially, crystals diffracted
strongly to better than 2.00 AÊ resolution, but
after 18 h of exposure to X-rays the intensity
of re¯ections had decreased by more than
66%. Therefore, it was necessary to develop
a cryocooling strategy to minimize crystal
radiation damage. The cryocooled crystals
have slightly contracted unit-cell para-
meters, a = 64.6, b = 70.0, c = 77.1 AÊ . Based
on one protein molecule per asymmetric
unit, the solvent content for the cryocooled
crystals is calculated to be 51%
(Vm = 2.3 AÊ
3 Daÿ1), compared with 54% for
the room-temperature crystals. These values
are within the expected range for proteins
(Matthews, 1968). Data-collection statistics
are summarized in Table 1. Attempts to
solve the structure by molecular replace-
ment using the C-terminal domain of the red
kidney bean enzyme have not been
successful. Consequently, the techniques of
multiple isomorphous replacement (MIR)
or multiwavelength anomalous diffraction
(MAD) will be investigated to solve the
phase problem. Several promising heavy-
atom derivatives for MIR have already been
identi®ed. The high-resolution diffraction
data from the measured cryocooled crystals
should enable determination of a very
accurate structure for mammalian purple
acid phosphatase, which will be an important
factor in the future success of structure-
based drug-design studies.
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